CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!
<< View More Conferences
14th International Conference on Malignant Lymphoma
Oncology Conference Multimedia
View more videos >>
Dr. Cheah on Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma
Dr. Fama on GBV-C Infection and Risk of Lymphoma
Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma
Oncology Conference Articles
Rituximab/Lenalidomide Combo Shows Promise for Indolent Lymphomas
Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.
JCAR017 Impresses in Updated DLBCL Data
Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.
Pembrolizumab Plus Rituximab Promising in Follicular Lymphoma
Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.
Copanlisib Lymphoma Data Updated as FDA Considers Approval
Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.
Obinutuzumab Benefit in Frontline Follicular Lymphoma Sustained With Longer Follow-Up
At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.
BGB-3111 Plus Obinutuzumab Effective in CLL and Follicular Lymphoma
Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.
BGB-3111 Induces Robust Response in Waldenstrom Macroglobulinemia
BGB-3111, a highly specific BTK inhibitor, is active in patients with Waldenström macroglobulinemia, according to an interim analysis from an ongoing phase I trial.
Avelumab Active in Hodgkin Lymphoma
Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.
Tazemetostat Active in Follicular Lymphoma, DLBCL
Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced
-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.
Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma
High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.
Pembrolizumab Active in Relapsed Mediastinal Large B-Cell Lymphoma
Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.
Expert Discusses Ibrutinib/Venetoclax Combo in MCL
Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.
Axicabtagene Ciloleucel NHL Data Presented as FDA Weighs Approval
Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.
Tisagenlecleucel-T Highly Active, With Durable Responses in DLBCL
Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.
Burden of Cardiovascular Disease in Prostate Cancer
Ramalingam Weaves Through Expanding SCLC Landscape
The Role of Patient Education in Side Effect Management
A Whirlwind of Change in Lung Cancer
Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.